# Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

> **NCT04991948** · PHASE1 · RECRUITING · sponsor: **Celyad Oncology SA** · enrollment: 34 (estimated)

## Conditions studied

- Unresectable Metastatic Colorectal Cancer

## Interventions

- **DRUG:** CYAD-101
- **DRUG:** FOLFOX
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04991948
- **Lead sponsor:** Celyad Oncology SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-22
- **Primary completion:** 2023-08-21
- **Final completion:** 2038-05-25
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2022-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04991948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04991948, "Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04991948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*